Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?

American Journal of Alzheimer's Disease and other Dementias

Volumn 19, Issue 5, 2004, Pages 269-274

  Albensi, Benedict C ^a   Igoechi, Chiazor ^a   Janigro, Damir ^a   Ilkanich, Erin ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer 's disease; Brain injury; Dementia; Excitotoxicity; NMDA antagonist; NMDAR

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; BETA SECRETASE INHIBITOR; CALCIUM ION; CHOLINESTERASE INHIBITOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIZOCILPINE; DONEPEZIL; EXCITATORY AMINO ACID; GAMMA SECRETASE INHIBITOR; GLUTAMIC ACID; HYPOCHOLESTEROLEMIC AGENT; IFENPRODIL; MEMANTINE; METAL CHELATE; MITOGEN ACTIVATED PROTEIN KINASE 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NATURAL PRODUCT; PHENCYCLIDINE; PROTEIN KINASE (CALCIUM,CALMODULIN); SPIDER VENOM; TACRINE; TRAXOPRODIL;

ABSENCE; ALZHEIMER DISEASE; BRAIN INJURY; COMA; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; HALLUCINATION; HUMAN; LONG TERM POTENTIATION; NEUROPROTECTION; NONHUMAN; PROTEIN PHOSPHORYLATION; PSYCHOSIS; REVIEW; SYNAPTIC TRANSMISSION;

EID: 6044248961     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/153331750401900502     Document Type: Review

References (39)

1. Ikonomidou C, Turski L: Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 2002; 1(6): 383-386.
2. Roesler R, Quevedo J, Schroder N: Is it time to conclude that NMDA antagonists have failed? Lancet Neurol. 2003; 2(1): 13.
3. Smith PF: Therapeutic N-methyl-D-aspartate receptor antagonists: Will reality meet expectation? Curr Opin Investig Drugs. 2003; 4(7): 826-832.
4. Scarpini E, Scheltens P, Feldman H: Treatment of Alzheimer's disease: Current status and new perspectives. Lancet Neurol. 2003; 2(9): 539-547.
5. van Reekum R, Black SE, Conn D, et al.: Cognition-enhancing drugs in dementia: A guide to the near future. Can J Psychiatry. 1997; 42(Suppl 1):35S-50S.
6. Mondadori C: Nootropics: Preclinical results in the light of clinical effects; Comparison with tacrine. Crit Rev Neurobiol. 1996; 10(3-4): 357-370.
7. Mayeux R, Sano M: Treatment of Alzheimer's disease. N Engl J Med. 1999; 341(22): 1670-1679.
8. Mattson MP, Furukawa K, Bruce AJ, et al.: Calcium homeostasis and free radical metabolism as convergence points in the pathophysiology of dementia. In Wasco W, Tanzi RE: Molecular Mechanisms of Dementia. Totowa, NJ: Humana Press, 1997.
9. Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003; 9(3): 275-308.
10. Muller WE, Mutschler E, Riederer P: Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry. 1995; 28(4): 113-124.
11. Masliah E, Raber J, Alford M, et al.: Amyloid protein precursor stimulates excitatory amino acid transport. J Biol Chem. 1998; 273(20): 12548-12554.
12. Yamada KA: Modulating excitatory synaptic neurotransmission: Potential treatment for neurological disease? Neurobiol Dis. 1998; 5(2): 67-80.
13. Watkins SC: The NMDA concept: Origins and developments. In Collingbridge GL, Watkins JC (eds.): The NMDA Receptor. Second Edition. Oxford: Oxford University Press, 1994.
14. Yun L, Zhang J: Recent development in NMDA receptors. Chin Med J. 2000; 113(10): 948-956.
15. Craig AM, Blackstone CD, Huganir RL, et al.: Selective clustering of glutamate and gamma-aminobutyric acid receptors opposite terminals releasing the corresponding neurotransmitters. Proc Natl Acad Sci USA. 1994; 91(26): 12373-12377.
16. Dodt HU, Frick A, Kampe K, et al.: NMDA and AMPA receptors on neocortical neurons are differentially distributed. Eur J Neurosci. 1998; 10(11): 3351-3357.
17. Sattler R, Xiong Z, Lu W, et al.: Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. J Neurosci. 2000; 20(1): 22-33.
18. McIlhinney RA, Philipps E, Le Bourdelles B, et al.: Assembly of N-methyl-D-aspartate (NMDA) receptors. Biochem Soc Trans. 2003; 31(Pt 4): 865-868.
19. Flint AC, Maisch US, Weishaupt JH, et al.: NR2A subunit expression shortens NMDA receptor synaptic currents in developing neocortex. J Neurosci. 1997; 17(7): 2469-2476.
20. Cull-Candy S, Brickley S, Farrant M: NMDA receptor subunits: Diversity, development and disease. Curr Opin Neurobiol. 2001; 11(3): 327-335.
21. Wild GC, Benzel EC: Essentals of Neurochemistry. Boston, London: Jones and Bartlett Publishers, 1994.
22. Petrenko AB, Yamakura T, Baba H, et al.: The Role of N-methyl-d-Aspartate (NMDA) receptors in pain: A review. Anasth Analg. 2003; 97(4): 1108-1116.
23. Prybylowski K, Wenthold RJ: N-Methyl-D-aspartate receptors: Subunit assembly and trafficking to the synapse. J Biol Chem. 2004; 279(11): 9673-9676.
24. Collingridge GL, Watkins JC: The NMDA Receptor. Oxford, New York, Tokyo: Oxford University Press, 1994.
25. Hardingham GE, Bading H: The Yin and Yang of NMDA receptor signaling. Trends Neurosci. 2003; 26(2): 81-89.
26. Haberny KA, Paule MG, Scallet AC, et al: Ontogeny of the N-methyl-D-aspartate (NMDA) receptor system and susceptibility to neurotoxicity. Toxicol Sci. 2002; 68(1): 9-17.
27. Deutsch SI, Mastropaolo J, Rosse RB: Neurodevelopmental consequences of early exposure to phencyclidine and related drugs. Clin Neuropharmacol. 1998; 21(6): 320-322.
28. Klitgaard H, Matagne A, Lamberty Y: Use of epileptic animals for adverse effect testing. Epilepsy Res. 2002; 50(1-2): 55-65.
29. Ikonomidou C, Bosch F, Miksa M, et al.: Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999; 283(5398): 70-74.
30. Hlinak Z, Krejci I: MK-801 induced amnesia for the elevated plus-maze in mice. Behav Brain Res. 2002; 131(1-2): 221-225.
31. Sharp FR, Tomitaka M, Bernaudin M, et al.: Psychosis: Pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci. 2001; 24(6): 330-334.
32. Albensi BC, Alasti N, Mueller AL: Long-term potentiation in the presence of NMDA receptor antagonist arylalkylamine spider toxins. J Neurosci Res. 2000; 62(2): 177-185.
33. Parks TN, Mueller AL, Artman LD, et al.: Arylamine toxins from funnel-web spider (Agelenopsis aperta) venom antagonize N-methyl-D-aspartate receptor function in mammalian brain. J Biol Chem. 1991; 266(32): 21523-21529.
34. Chazot PL: The NMDA receptor NR2B subunit: A valid therapeutic target for multiple CNS pathologies. Curr Med Chem. 2004; 11: 389-396.
35. Chazot PL: CP-101606. Curr Opin Invest New Drugs. 2000; 1(3): 370-374.
36. Nikam SS, Meltzer LT: NR2B selective NMDA receptor antagonists. Curr Pharm Design. 8(10): 845-855.
37. Jarvis B, Figgitt DP: Memantine. Drugs Aging. 2003; 20(6): 465-476.
38. Reisberg B, Doody R, Stöffler A, et al.: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348(14): 1333-1341.
39. Feret B, Dicks R: Memantine. Formulary. 2004; 39: 91-103.